These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 30378502)

  • 1. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
    Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of clinical envelopes with lack of sensitivity to the HIV-1 inhibitors temsavir and ibalizumab.
    Gartland M; Stewart E; Zhou N; Li Z; Rose R; Beloor J; Clark A; Tenorio AR; Krystal M
    Antiviral Res; 2024 Aug; 228():105957. PubMed ID: 38971430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy.
    Cluck DB; Chastain DB; Murray M; Durham SH; Chahine EB; Derrick C; Dumond JB; Hester EK; Jeter SB; Johnson MD; Kilcrease C; Kufel WD; Kwong J; Ladak AF; Patel N; Pérez SE; Poe JB; Bolch C; Thomas I; Asiago-Reddy E; Short WR
    Pharmacotherapy; 2024 May; 44(5):360-382. PubMed ID: 38853601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summary.
    Cluck DB; Chastain DB; Murray M; Durham SH; Chahine EB; Derrick C; Dumond JB; Hester EK; Jeter SB; Johnson MD; Kilcrease C; Kufel WD; Kwong J; Ladak AF; Patel N; Pérez SE; Poe JB; Bolch C; Thomas I; Asiago-Reddy E; Short WR
    Pharmacotherapy; 2024 May; 44(5):354-359. PubMed ID: 38853605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure-Response Analysis.
    Lagishetty C; Moore K; Ackerman P; Llamoso C; Magee M
    Clin Transl Sci; 2020 Jul; 13(4):769-776. PubMed ID: 32027457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study.
    Llibre JM; Aberg JA; Walmsley S; Velez J; Zala C; Crabtree Ramírez B; Shepherd B; Shah R; Clark A; Tenorio AR; Pierce A; Du F; Li B; Wang M; Chabria S; Warwick-Sanders M
    Front Immunol; 2024; 15():1394644. PubMed ID: 38863717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Antiretroviral Agents.
    Cambou MC; Landovitz RJ
    Curr HIV/AIDS Rep; 2020 Apr; 17(2):118-124. PubMed ID: 32052271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States.
    Millham LRI; Scott JA; Sax PE; Shebl FM; Reddy KP; Losina E; Walensky RP; Freedberg KA
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):148-156. PubMed ID: 31929403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fostemsavir to overcome drug-drug interactions in heavily treatment-experienced people with HIV and cancer.
    Giacomelli A; Cattaneo D; Pozza G; Moschese D; Cossu MV; Dalu D; Gervasoni C
    J Antimicrob Chemother; 2024 Jul; 79(7):1708-1709. PubMed ID: 38661237
    [No Abstract]   [Full Text] [Related]  

  • 10. Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.
    Bachelard A; Le Hingrat Q; Ferré VM; Lê M; Peytavin G; Damond F; Charpentier C; Fremont Goudot G; Goupil de Bouille J; Lariven S; Delobel P; Yazdanpanah Y; Descamps D; Matheron S; Ghosn J;
    Clin Infect Dis; 2024 Apr; 78(4):1005-1010. PubMed ID: 38630945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
    Kozal M; Aberg J; Pialoux G; Cahn P; Thompson M; Molina JM; Grinsztejn B; Diaz R; Castagna A; Kumar P; Latiff G; DeJesus E; Gummel M; Gartland M; Pierce A; Ackerman P; Llamoso C; Lataillade M;
    N Engl J Med; 2020 Mar; 382(13):1232-1243. PubMed ID: 32212519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fostemsavir: First Approval.
    Markham A
    Drugs; 2020 Sep; 80(14):1485-1490. PubMed ID: 32852743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fostemsavir: A Novel Attachment Inhibitor for Patients With Multidrug-Resistant HIV-1 Infection.
    Hiryak K; Koren DE
    Ann Pharmacother; 2021 Jun; 55(6):792-797. PubMed ID: 32964736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
    Lataillade M; Lalezari JP; Kozal M; Aberg JA; Pialoux G; Cahn P; Thompson M; Molina JM; Moreno S; Grinsztejn B; Diaz RS; Castagna A; Kumar PN; Latiff GH; De Jesus E; Wang M; Chabria S; Gartland M; Pierce A; Ackerman P; Llamoso C
    Lancet HIV; 2020 Nov; 7(11):e740-e751. PubMed ID: 33128903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis.
    Michienzi SM; Schriever CA; Badowski ME
    Int J STD AIDS; 2019 Feb; 30(2):181-187. PubMed ID: 30381029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viremia copy-years and mortality among combination antiretroviral therapy-initiating HIV-positive individuals: how much viral load history is enough?
    Wang R; Haberlen SA; Palella FJ; Mugavero MJ; Margolick JB; Macatangay BJC; Martínez-Maza O; Jacobson LP; Abraham AG
    AIDS; 2018 Nov; 32(17):2547-2556. PubMed ID: 30379686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibalizumab for the treatment of multidrug-resistant HIV-1 infection.
    Rizza SA; Bhatia R; Zeuli J; Temesgen Z
    Drugs Today (Barc); 2019 Jan; 55(1):25-34. PubMed ID: 30740610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection.
    Blair HA
    Drugs; 2020 Feb; 80(2):189-196. PubMed ID: 31970712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years.
    Najjar A; Najjar A; Karaman R
    Molecules; 2020 Feb; 25(4):. PubMed ID: 32079289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Stellbrink HJ; Arribas JR; Stephens JL; Albrecht H; Sax PE; Maggiolo F; Creticos C; Martorell CT; Wei X; Acosta R; Collins SE; Brainard D; Martin H
    Lancet HIV; 2019 Jun; 6(6):e364-e372. PubMed ID: 31068272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.